Vimarsana
Biggest News Aggregation in the World

Page 41 - Ioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ioscience Today - Breaking & Trending Today

Arix Bioscience PLC: Clinical Development Update from Portfolio Company LogicBio - Vimarsana News

Arix Bioscience PLC: Clinical Development Update from Portfolio Company LogicBio

DJ Clinical Development Update from Portfolio Company LogicBio Arix Bioscience PLC (ARIX) Clinical Development Update from Portfolio Company LogicBio 09-May-2022 / 15:28 GMT/BST Dissemination of

Satellos Bioscience Inc.: Satellos Bioscience Announces 2021 Year End Financial Results and Operational Highlights - Vimarsana News

Satellos Bioscience Inc.: Satellos Bioscience Announces 2021 Year End Financial Results and Operational Highlights

Toronto, Ontario--(Newsfile Corp. - April 29, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change

Arix Bioscience PLC: Unaudited NAV and Notice of Financial Results - Vimarsana News

Arix Bioscience PLC: Unaudited NAV and Notice of Financial Results

DJ Unaudited NAV and Notice of Financial Results Arix Bioscience PLC (ARIX) Unaudited NAV and Notice of Financial Results 29-Apr-2022 / 10:44 GMT/BST Dissemination of a Regulatory Announcement, transmitted

Lexaria Bioscience Corp.: Lexaria Granted Patent for Use of DehydraTECH to Deliver Antiviral Drugs - Vimarsana News

Lexaria Bioscience Corp.: Lexaria Granted Patent for Use of DehydraTECH to Deliver Antiviral Drugs

25th patent grant is Lexaria's first-ever patent for the enhanced delivery of antiviralsKELOWNA, BC / ACCESSWIRE / April 21, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company"

Lexaria Bioscience Corp.: Lexaria Commences Multi-Week Human Clinical Hypertension Study - Vimarsana News

Lexaria Bioscience Corp.: Lexaria Commences Multi-Week Human Clinical Hypertension Study

HYPER-H21-4 will evaluate DehydraTECHTM-CBD for reducing blood pressure together with other potential clinical benefitsThis study is designed to enhance Lexaria's probabilities of success with its expected